{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:09:36Z","timestamp":1789664976419,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ijantimicag.2019.06.021","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T16:50:33Z","timestamp":1562172633000},"page":"292-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis"],"prefix":"10.1016","volume":"54","author":[{"given":"Yuka","family":"Ohata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2019.06.021_bib0001","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1093\/clind\/15.Supplement_1.S182","article-title":"Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis","volume":"15","author":"McCracken","year":"1992","journal-title":"Clin infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0002","series-title":"Practice guideline for bacterial meningitis 2014","year":"2014"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0003","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0004","series-title":"Guide to clinical management of infectious diseases","year":"2014"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2019.06.021_bib0005","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0007","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0149-2918(04)80001-8","article-title":"Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem","volume":"26","author":"Mattoes","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0008","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.02.018","article-title":"Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections","volume":"28","author":"Kuti","year":"2006","journal-title":"Int J Antimicrobial Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1469-0691.2007.01693.x","article-title":"Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modeling: application to meropenem dosage and combination therapy","volume":"13","author":"Filho","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0011","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10156-007-0562-3","article-title":"Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation","volume":"13","author":"Watanabe","year":"2007","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0012","first-page":"159","article-title":"The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation","volume":"58","author":"Mikamo","year":"2005","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0013","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10156-011-0271-9","article-title":"Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis","volume":"17","author":"Ohata","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ijantimicag.2007.06.005","article-title":"Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003\u20132004","volume":"30","author":"Wang","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0015","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jac\/dkm325","article-title":"Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modeling and Monte Carlo simulation","volume":"60","author":"Lodise","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0016","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1179\/joc.2008.20.5.615","article-title":"The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients","volume":"20","author":"Tsumura","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0017","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1128\/AAC.00997-16","article-title":"Population pharmacokinetics and dosing regimen optimization of meropenem in cerebrospinal fluid and plasma in patients with meningitis after neurosurgery","volume":"60","author":"Lu","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0018","first-page":"343","article-title":"Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study","volume":"20","author":"Blassmann","year":"2016","journal-title":"Clin Care"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0019","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/515003","article-title":"Antibiotic pharmacodynamics in cerebrospinal fluid","volume":"27","author":"Lutsar","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0020","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1469-8749.1985.tb04581.x","article-title":"The development of the human blood\u2013CSF\u2013brain barrier","volume":"27","author":"Adinolfi","year":"1985","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/34.1.175","article-title":"Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges","volume":"34","author":"Dagan","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0022","first-page":"762","article-title":"Clinical study of meropenem for infections in the paediatric field","volume":"51","author":"Toyonaga","year":"2003","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0023","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00006454-199907000-00004","article-title":"Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children","volume":"18","author":"Odio","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jiac.2014.04.013","article-title":"Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan","volume":"20","author":"Morita","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0025","series-title":"Center for Veterinary Medicine, Guidance for Industry: Bioanalytical method validation","article-title":"Food and Drug Administration, Center for Drug Evaluation and Research","year":"2001"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0026","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2133\/dmpk.DMPK-11-RG-027","article-title":"Optimal dosage regimen of meropenem for paediatric patients based on pharmacokinetic\/pharmacodynamic consideration","volume":"26","author":"Ohata","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0027","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"1988"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0028","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria","year":"1990"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0029","series-title":"Performance standards for antimicrobial disk susceptibility tests","year":"1993"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0030","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"1997"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0031","series-title":"Center for Biologics Evaluation and Research, Guidance for Industry: Population Pharmacokinetics","article-title":"Food and Drug Administration, Center for Drug Evaluation and Research","year":"1999"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0032","series-title":"Committee for Medicial Products for Human Use, Guideline on Reporting the Results of Population Pharmacokinetic Analyses","year":"2008"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0033","series-title":"NONMEM users guides: NONMEM Project Group","author":"Beal","year":"1992"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0034","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/brain\/91.4.707","article-title":"Formation and absorption of cerebrospinal fluid in man","volume":"91","author":"Cutler","year":"1968","journal-title":"Brain"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2019.06.021_bib0035","first-page":"145","article-title":"Pharmacokinetics of [C14] meropenem in dogs and monkeys [in Japanese]","volume":"40","author":"Iba","year":"1992","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0036","first-page":"73","article-title":"Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012","volume":"67","author":"Yamaguchi","year":"2014","journal-title":"Jap J Antibiot"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0037","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. 2019. Available at:http:\/\/www.eucast.org."},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0038","series-title":"Textbook of medical physiology","author":"Guyton","year":"2006"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0039","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/infdis\/jix211","article-title":"White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs","volume":"216","author":"Boucher","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.021_bib0040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/infdis\/jix212","article-title":"Stepping off the resistance treadmill","volume":"216","author":"Drusano","year":"2017","journal-title":"J Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T11:17:20Z","timestamp":1567077440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0924857919301748"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.021","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}